Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Argenta Announces Fourth Extension of Drug Discovery Collaboration with Genentech

Published: Monday, October 14, 2013
Last Updated: Monday, October 14, 2013
Bookmark and Share
Agreement covers a portfolio of projects that utilizes Argenta's drug discovery expertise.

Argenta has announced a three-year extension of its integrated contract drug discovery agreement with Genentech, a member of the Roche Group.

This is the fourth such extension since the agreement was first announced in December 2005. The agreement covers a portfolio of projects that utilizes Argenta's wide-ranging drug discovery expertise to discover new chemical entities acting against undisclosed drug targets defined by Genentech.

Dr John Montana, Managing Director of Argenta, commented, “We are delighted that our long-standing and highly valued client, Genentech, has once again chosen to extend its collaboration with Argenta. We believe that this further extension is a testament both to the close working relationship that has been established between our companies over the years and the high level of success delivered by Argenta to Genentech in terms of pre-clinical candidate compounds, four of which are currently in clinical trials”.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Argenta Expands Collaboration with Genentech to Include BioFocus
Under the amendment, BioFocus will provide Genentech with integrated medicinal chemistry, in vitro biology and ADME services.
Thursday, September 16, 2010
Argenta Discovery Announces Two-Year Extension of Major Drug Discovery Collaboration with Genentech
This is the second extension of the contract drug discovery agreement since the first collaboration was announced in December 2005.
Friday, May 22, 2009
Argenta Discovery and Porsolt Join Forces to Provide CNS and Pain Contract Drug Discovery Services
The collaboration enables Argenta and Porsolt to undertake fully integrated CNS and pain-focused drug discovery programmes for clients.
Wednesday, May 20, 2009
Argenta Discovery collaboration with Corcept Therapeutics

Wednesday, May 07, 2003
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos